Exact Sciences stock gains on a $290 million quarter
Published on 08/25/2026 at 18:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences (US30063P1057) stock has a new numbers set after the company filed second-quarter 2026 results on August 25, 2026, showing $290 million in revenue and an adjusted loss of $0.39 per share. The filing also confirms the release was tied to the quarter ended August 2, 2026, giving investors a fresh reporting anchor.
Quarterly scorecard
The second-quarter 2026 update matters because it turns the discussion back to execution, not just valuation. Revenue of $290 million and an adjusted loss of $0.39 per share set the base for the next read-through on margins and operating leverage.
That comparison is more useful when set against the company’s own recent history: the quarter ended August 2, 2026, is the most recent reported period in the filing, and it is the metric set that now frames sentiment into the next catalyst window.
Market context
For investors, the market side of the story should stay anchored to the latest completed session and the company’s current valuation band. Exact Sciences remains a health-care diagnostics name where revenue progress and profitability trends carry more weight than broad market tone.
The key read-through from August 25 is simple: a $290 million quarter is the visible current benchmark, and the next debate is whether the business can turn that scale into a narrower loss profile over the following periods.
Product line
Cologuard remains the company’s best-known screening test and the product most tied to Exact Sciences' revenue narrative. That makes the installed base and screening adoption trend more important than any one quarter in isolation.
Exact Sciences shares now
Exact Sciences shares now trade around their most recent market reference point, while the second-quarter 2026 filing supplies the latest hard numbers for revenue and adjusted earnings.
Fact box
Company: Exact Sciences
ISIN: US30063P1057
Ticker: EXAS
Exchange: Nasdaq
Sector / Industry: Health Care / Diagnostics & Research
Index membership: Nasdaq-100
Next earnings date: August 25, 2026
More on Exact Sciences
Exact Sciences builds its business around cancer screening and diagnostics, with Cologuard as the main consumer-facing test.
More on Exact Sciences stock
Exact Sciences stock is now framed by the second-quarter 2026 filing and the quarter ended August 2, 2026, which set the freshest operating benchmark in the current reporting cycle.
